Minocycline influences the anti-inflammatory interleukins and enhances the effectiveness of morphine under mice diabetic neuropathy

Journal of Neuroimmunology

Volumn 262, Issue 1-2, 2013, Pages 35-45

  Zychowska, Magdalena ^a   Rojewska, Ewelina ^a   Kreiner, Grzegorz ^a   Nalepa, Irena ^a   Przewlocka, Barbara ^a   Mika, Joanna ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Antibody array; Cytokines; Diabetic neuropathic pain; Microglia; Minocycline; Morphine

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 9; MINOCYCLINE; MORPHINE; TUMOR NECROSIS FACTOR RECEPTOR 2;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; DIABETIC NEUROPATHY; DISEASE MODEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENTIATION; HYPERALGESIA; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; MACROGLIA; MALE; MICROGLIA; MOUSE; NEUROPATHIC PAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

ANTIBODY ARRAY; CYTOKINES; DIABETIC NEUROPATHIC PAIN; MICROGLIA; MINOCYCLINE; MORPHINE;

ANALGESICS, OPIOID; ANIMALS; DIABETIC NEUROPATHIES; DISEASE MODELS, ANIMAL; INFLAMMATION MEDIATORS; INTERLEUKINS; MALE; MICE; MINOCYCLINE; MORPHINE; NEURALGIA; UP-REGULATION;

EID: 84884163395     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2013.06.005     Document Type: Article

References (93)

1. Alano C.C., Kauppinen T.M., Valls A.V., Swanson R.A. Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:9685-9690.
2. Beiswenger K.K., Calcutt N.A., Mizisin A.P. Dissociation of thermal hypoalgesia and epidermal denervation in streptozotocin-diabetic mice. Neurosci. Lett. 2008, 442:267-272.
3. Bennett R.A., Pegg A.E. Alkylation of DNA in rat tissues following administration of streptozotocin. Cancer Res. 1981, 41:2786-2790.
4. Bishnoi M., Bosgraaf C.A., Abooj M., Zhong L., Premkumar L.S. Streptozotocin-induced early thermal hyperalgesia is independent of glycemic state of rats: role of transient receptor potential vanilloid 1(TRPV1) and inflammatory mediators. Mol. Pain 2011, 7:52.
5. Boulton A.J., Gries F.A., Jervell J.A. Guidelines for the diagnosis and outpatient management of diabetic peripheral neuropathy. Diabet. Med. 1998, 15:508-514.
6. Burkart V., Wang Z.Q., Radons J., Heller B., Herceg Z., Stingl L., et al. Mice lacking the poly(ADP-ribose) polymerase gene are resistant to pancreatic beta-cell destruction and diabetes development induced by streptozocin. Nat. Med. 1999, 5:314-319.
7. Calcutt N.A. Experimental models of painful diabetic neuropathy. J. Neurol. Sci. 2004, 220:137-139.
8. Calcutt N.A., Jorge M.C., Yaksh T.L., Chaplan S.R. Tactile allodynia and formalin hyperalgesia in streptozotocin-diabetic rats: effects of insulin, aldose reductase inhibition and lidocaine. Pain 1996, 68:293-299.
9. Cata J.P., Weng H.R., Dougherty P.M. The effects of thalidomide and minocycline on taxol-induced hyperalgesia in rats. Brain Res. 2008, 1229:100-110.
10. Chen S.R., Pan H.L. Antinociceptive effect of morphine, but not mu opioid receptor number, is attenuated in the spinal cord of diabetic rats. Anesthesiology 2003, 99:1409-1414.
11. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 1987, 162:156-159.
12. Colburn R.W., Rickman A.J., DeLeo J.A. The effect of site and type of nerve injury on spinal glial activation and neuropathic pain behavior. Exp. Neurol. 1999, 157:289-304.
13. Courteix C., Bourget P., Caussade F., Bardin M., Coudore F., Fialip J., et al. Is the reduced efficacy of morphine in diabetic rats caused by alterations of opiate receptors or of morphine pharmacokinetics?. J. Pharmacol. Exp. Ther. 1998, 285:63-70.
14. Coyle D.E. Partial peripheral nerve injury leads to activation of astroglia and microglia which parallels the development of allodynic behavior. Glia 1998, 23:75-83.
15. Cui Y., Liao X.X., Liu W., Guo R.X., Wu Z.Z., Zhao C.M., et al. A novel role of minocycline: attenuating morphine antinociceptive tolerance by inhibition of p38 MAPK in the activated spinal microglia. Brain Behav. Immun. 2008, 22:114-123.
16. Cukras C.A., Petrou P., Chew E.Y., Meyerle C.B., Wong W.T. Oral minocycline for the treatment of diabetic macular edema (DME): results of a phase I/II clinical study. Invest. Ophthalmol. Vis. Sci. 2012, 53:3865-3874.
17. Daulhac L., Mallet C., Courteix C., Etienne M., Duroux E., Privat A.M., et al. Diabetes-induced mechanical hyperalgesia involves spinal mitogen-activated protein kinase activation in neurons and microglia via N-methyl-d-aspartate-dependent mechanisms. Mol. Pharmacol. 2006, 70:1246-1254.
18. Davidson E., Coppey L., Lu B., Arballo V., Calcutt N.A., Gerard C., et al. The roles of streptozotocin neurotoxicity and neutral endopeptidase in murine experimental diabetic neuropathy. Exp. Diabetes Res. 2009, 2009:431980.
19. Dogrul A., Gul H., Yesilyurt O., Ulas U.H., Yildiz O. Systemic and spinal administration of etanercept, a tumor necrosis factor alpha inhibitor, blocks tactile allodynia in diabetic mice. Acta Diabetol. 2011, 48:135-142.
20. Dogrul A., Gul H., Yildiz O., Bilgin F., Guzeldemir M.E. Cannabinoids blocks tactile allodynia in diabetic mice without attenuation of its antinociceptive effect. Neurosci. Lett. 2004, 368:82-86.
21. Ehrt S., Schnappinger D., Bekiranov S., Drenkow J., Shi S., Gingeras T.R., et al. Reprogramming of the macrophage transcriptome in response to interferon-gamma and Mycobacterium tuberculosis: signaling roles of nitric oxide synthase-2 and phagocyte oxidase. J. Exp. Med. 2001, 194:1123-1140.
22. Elsner M., Guldbakke B., Tiedge M., Munday R., Lenzen S. Relative importance of transport and alkylation for pancreatic beta-cell toxicity of streptozotocin. Diabetologia 2000, 43:1528-1533.
23. Francés D.E., Ingaramo P.I., Mayoral R., Través P., Casado M., Valverde Á.M., Martín-Sanz P., Carnovale C.E. Cyclooxygenase-2 over-expression inhibits liver apoptosis induced by hyperglycemia. J. Cell. Biochem. 2013, 114:669-680.
24. Fujimoto H., Hirase T., Miyazaki Y., Hara H., Ide-Iwata N., Nishimoto-Hazuku A., et al. IL-27 inhibits hyperglycemia and pancreatic islet inflammation induced by streptozotocin in mice. Am. J. Pathol. 2011, 179:2327-2336.
25. Gabra B.H., Sirois P. Beneficial effect of chronic treatment with the selective bradykinin B1 receptor antagonists, R-715 and R-954, in attenuating streptozotocin-diabetic thermal hyperalgesia in mice. Peptides 2003, 24:1131-1139.
26. Garrido-Mesa N., Zarzuelo A., Galvez J. What is behind the non-antibiotic properties of minocycline?. Pharmacol. Res. 2012, 67:18-30.
27. Gezginci-Oktayoglu S., Sacan O., Yanardag R., Karatug A., Bolkent S. Exendin-4 improves hepatocyte injury by decreasing proliferation through blocking NGF/TrkA in diabetic mice. Peptides 2011, 32:223-231.
28. Gordon S. Alternative activation of macrophages. Nat. Rev. Immunol. 2003, 3:23-35.
29. Gul H., Yildiz O., Dogrul A., Yesilyurt O., Isimer A. The interaction between IL-1beta and morphine: possible mechanism of the deficiency of morphine-induced analgesia in diabetic mice. Pain 2000, 89:39-45.
30. Hains B.C., Waxman S.G. Activated microglia contribute to the maintenance of chronic pain after spinal cord injury. J. Neurosci. 2006, 26:4308-4317.
31. Haligur M., Topsakal S., Ozmen O. Early degenerative effects of diabetes mellitus on pancreas, liver, and kidney in rats: an immunohistochemical study. Exp. Diabetes Res. 2012, 2012:120645.
32. Hong S., Morrow T.J., Paulson P.E., Isom L.L., Wiley J.W. Early painful diabetic neuropathy is associated with differential changes in tetrodotoxin-sensitive and -resistant sodium channels in dorsal root ganglion neurons in the rat. J. Biol. Chem. 2004, 279:29341-29350.
33. Jain S.K., Rains J.L., Croad J.L. Effect of chromium niacinate and chromium picolinate supplementation on lipid peroxidation, TNF-alpha, IL-6, CRP, glycated hemoglobin, triglycerides, and cholesterol levels in blood of streptozotocin-treated diabetic rats. Free Radic. Biol. Med. 2007, 43:1124-1131.
34. Ji R.R., Xu Z.Z., Wang X., Lo E.H. Matrix metalloprotease regulation of neuropathic pain. Trends Pharmacol. Sci. 2009, 30:336-340.
35. Jiang C.L., Xu D., Lu C.L., Wang Y.X., You Z.D., Liu X.Y. Interleukin-2: structural and biological relatedness to opioid peptides. Neuroimmunomodulation 2000, 8:20-24.
36. Kanki H., Fukuda K., Okushi K., Ibata I., Toyama Y., Shimizu H., et al. Comparison of nerve growth factor mRNA expression in cardiac and skeletal muscle in streptozotocin-induced diabetic mice. Life Sci. 1999, 65:2305-2313.
37. Kapur D. Neuropathic pain and diabetes. Diabetes Metab. Res. Rev. 2003, 19(Suppl. 1):S9-S15.
38. Kennedy J.M., Zochodne D.W. The regenerative deficit of peripheral nerves in experimental diabetes: its extent, timing and possible mechanisms. Brain 2000, 123(Pt 10):2118-2129.
39. Krady J.K., Basu A., Allen C.M., Xu Y., LaNoue K.F., Gardner T.W., et al. Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. Diabetes 2005, 54:1559-1565.
40. Kreutzberg G.W. Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 1996, 19:312-318.
41. Ledeboer A., Sloane E.M., Milligan E.D., Frank M.G., Mahony J.H., Maier S.F., et al. Minocycline attenuates mechanical allodynia and proinflammatory cytokine expression in rat models of pain facilitation. Pain 2005, 115:71-83.
42. Lenzen S. The mechanisms of alloxan- and streptozotocin-induced diabetes. Diabetologia 2008, 51:216-226.
43. Lin S., Zhang Y., Dodel R., Farlow M.R., Paul S.M., Du Y. Minocycline blocks nitric oxide-induced neurotoxicity by inhibition p38 MAP kinase in rat cerebellar granule neurons. Neurosci. Lett. 2001, 315:61-64.
44. Lin S.J., Tu Y.K., Tsai S.C., Lai S.M., Lu H.K. Non-surgical periodontal therapy with and without subgingival minocycline administration in patients with poorly controlled type II diabetes: a randomized controlled clinical trial. Clin. Oral Investig. 2012, 16:599-609.
45. Lynch J.J., Jarvis M.F., Kowaluk E.A. An adenosine kinase inhibitor attenuates tactile allodynia in a rat model of diabetic neuropathic pain. Eur. J. Pharmacol. 1999, 364:141-146.
46. Martinez F.O., Sica A., Mantovani A., Locati M. Macrophage activation and polarization. Front. Biosci. 2008, 13:453-461.
47. Migita K., Moriyama T., Koguchi M., Honda K., Katsuragi T., Takano Y., et al. Modulation of P2X receptors in dorsal root ganglion neurons of streptozotocin-induced diabetic neuropathy. Neurosci. Lett. 2009, 452:200-203.
48. Mika J., Korostynski M., Kaminska D., Wawrzczak-Bargiela A., Osikowicz M., Makuch W., et al. Interleukin-1 alpha has antiallodynic and antihyperalgesic activities in a rat neuropathic pain model. Pain 2008, 138:587-597.
49. Mika J., Obara I., Przewlocka B. The role of nociceptin and dynorphin in chronic pain: implications of neuro-glial interaction. Neuropeptides 2011, 45:247-261.
50. Mika J., Osikowicz M., Makuch W., Przewlocka B. Minocycline and pentoxifylline attenuate allodynia and hyperalgesia and potentiate the effects of morphine in rat and mouse models of neuropathic pain. Eur. J. Pharmacol. 2007, 560:142-149.
51. Mika J., Rojewska E., Makuch W., Przewlocka B. Minocycline reduces the injury-induced expression of prodynorphin and pronociceptin in the dorsal root ganglion in a rat model of neuropathic pain. Neuroscience 2010, 165:1420-1428.
52. Mika J., Wawrzczak-Bargiela A., Osikowicz M., Makuch W., Przewlocka B. Attenuation of morphine tolerance by minocycline and pentoxifylline in naive and neuropathic mice. Brain Behav. Immun. 2009, 23:75-84.
53. Milligan E.D., Watkins L.R. Pathological and protective roles of glia in chronic pain. Nat. Rev. Neurosci. 2009, 10:23-36.
54. Morgado C., Pereira-Terra P., Cruz C.D., Tavares I. Minocycline completely reverses mechanical hyperalgesia in diabetic rats through microglia-induced changes in the expression of the potassium chloride co-transporter 2 (KCC2) at the spinal cord. Diabetes Obes. Metab. 2011, 13:150-159.
55. Moss A., Beggs S., Vega-Avelaira D., Costigan M., Hathway G.J., Salter M.W., et al. Spinal microglia and neuropathic pain in young rats. Pain 2007, 128:215-224.
56. Murakami T., Iwanaga T., Ogawa Y., Fujita Y., Sato E., Yoshitomi H., et al. Development of sensory neuropathy in streptozotocin-induced diabetic mice. Brain Behav. 2013, 3:35-41.
57. Nielsen C.K., Ross F.B., Lotfipour S., Saini K.S., Edwards S.R., Smith M.T. Oxycodone and morphine have distinctly different pharmacological profiles: radioligand binding and behavioural studies in two rat models of neuropathic pain. Pain 2007, 132:289-300.
58. Ohsawa M., Aasato M., Hayashi S.S., Kamei J. RhoA/Rho kinase pathway contributes to the pathogenesis of thermal hyperalgesia in diabetic mice. Pain 2011, 152:114-122.
59. Ohsawa M., Mizoguchi H., Narita M., Kamei J., Nagase H., Tseng L.F. Effects of a mu-opioid receptor agonist on G-protein activation in streptozotocin-induced diabetic mice. Eur. J. Pharmacol. 2000, 401:55-58.
60. Osikowicz M., Skup M., Mika J., Makuch W., Czarkowska-Bauch J., Przewlocka B. Glial inhibitors influence the mRNA and protein levels of mGlu2/3, 5 and 7 receptors and potentiate the analgesic effects of their ligands in a mouse model of neuropathic pain. Pain 2009, 147:175-186.
61. Pabreja K., Dua K., Sharma S., Padi S.S., Kulkarni S.K. Minocycline attenuates the development of diabetic neuropathic pain: possible anti-inflammatory and anti-oxidant mechanisms. Eur. J. Pharmacol. 2011, 661:15-21.
62. Park T.S., Park J.H., Baek H.S. Can diabetic neuropathy be prevented?. Diabetes Res. Clin. Pract. 2004, 66(Suppl. 1):S53-S56.
63. Pelegrin P., Surprenant A. Dynamics of macrophage polarization reveal new mechanism to inhibit IL-1beta release through pyrophosphates. EMBO J. 2009, 28:2114-2127.
64. Perry V.H., Matyszak M.K., Fearn S. Altered antigen expression of microglia in the aged rodent CNS. Glia 1993, 7:60-67.
65. Piao Z.G., Cho I.H., Park C.K., Hong J.P., Choi S.Y., Lee S.J., et al. Activation of glia and microglial p38 MAPK in medullary dorsal horn contributes to tactile hypersensitivity following trigeminal sensory nerve injury. Pain 2006, 121:219-231.
66. Plane J.M., Shen Y., Pleasure D.E., Deng W. Prospects for minocycline neuroprotection. Arch. Neurol. 2010, 67:1442-1448.
67. Raghavendra V., Rutkowski M.D., DeLeo J.A. The role of spinal neuroimmune activation in morphine tolerance/hyperalgesia in neuropathic and sham-operated rats. J. Neurosci. 2002, 22:9980-9989.
68. Rashid M.H., Inoue M., Bakoshi S., Ueda H. Increased expression of vanilloid receptor 1 on myelinated primary afferent neurons contributes to the antihyperalgesic effect of capsaicin cream in diabetic neuropathic pain in mice. J. Pharmacol. Exp. Ther. 2003, 306:709-717.
69. Rerup C.C. Drugs producing diabetes through damage of the insulin secreting cells. Pharmacol. Rev. 1970, 22:485-518.
70. Romagnani P., Annunziato F., Piccinni M.P., Maggi E., Romagnani S. Th1/Th2 cells, their associated molecules and role in pathophysiology. Eur. Cytokine Netw. 2000, 11:510-511.
71. Schafer M.K., Schwaeble W.J., Post C., Salvati P., Calabresi M., Sim R.B., et al. Complement C1q is dramatically up-regulated in brain microglia in response to transient global cerebral ischemia. J. Immunol. 2000, 164:5446-5452.
72. Simon G.S., Dewey W.L. Narcotics and diabetes. I. The effects of streptozotocin-induced diabetes on the antinociceptive potency of morphine. J. Pharmacol. Exp. Ther. 1981, 218:318-323.
73. Sinclair S.M., Shamji M.F., Chen J., Jing L., Richardson W.J., Brown C.R., et al. Attenuation of inflammatory events in human intervertebral disc cells with a tumor necrosis factor antagonist. Spine (Phila Pa 1976) 2011, 36:1190-1196.
74. Song P., Liu X.Y., Zhao Z.Q. Interleukin-2-induced antinociception in morphine-insensitive rats. Acta Pharmacol. Sin. 2002, 23:981-984.
75. Speth C., Dierich M.P., Gasque P. Neuroinvasion by pathogens: a key role of the complement system. Mol. Immunol. 2002, 38:669-679.
76. Sweitzer S.M., Medicherla S., Almirez R., Dugar S., Chakravarty S., Shumilla J.A., et al. Antinociceptive action of a p38alpha MAPK inhibitor, SD-282, in a diabetic neuropathy model. Pain 2004, 109:409-419.
77. Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol. Res. 2001, 50:537-546.
78. Talbot S., Chahmi E., Dias J.P., Couture R. Key role for spinal dorsal horn microglial kinin B1 receptor in early diabetic pain neuropathy. J. Neuroinflammation 2010, 7:36.
79. Tanga F.Y., Raghavendra V., DeLeo J.A. Quantitative real-time RT-PCR assessment of spinal microglial and astrocytic activation markers in a rat model of neuropathic pain. Neurochem. Int. 2004, 45:397-407.
80. Tsuda M., Ueno H., Kataoka A., Tozaki-Saitoh H., Inoue K. Activation of dorsal horn microglia contributes to diabetes-induced tactile allodynia via extracellular signal-regulated protein kinase signaling. Glia 2008, 56:378-386.
81. Tzartos J.S., Friese M.A., Craner M.J., Palace J., Newcombe J., Esiri M.M., et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am. J. Pathol. 2008, 172:146-155.
82. Valsecchi A.E., Franchi S., Panerai A.E., Rossi A., Sacerdote P., Colleoni M. The soy isoflavone genistein reverses oxidative and inflammatory state, neuropathic pain, neurotrophic and vasculature deficits in diabetes mouse model. Eur. J. Pharmacol. 2011, 650:694-702.
83. Vause C.V., Durham P.L. Identification of cytokines and signaling proteins differentially regulated by sumatriptan/naproxen. Headache 2012, 52:80-89.
84. Wang Y., Pei G., Cai Y.C., Zhao Z.Q., Wang J.B., Jiang C.L., et al. Human interleukin-2 could bind to opioid receptor and induce corresponding signal transduction. Neuroreport 1996, 8:11-14.
85. Watkins L.R., Hutchinson M.R., Johnston I.N., Maier S.F. Glia: novel counter-regulators of opioid analgesia. Trends Neurosci. 2005, 28:661-669.
86. Watkins L.R., Hutchinson M.R., Ledeboer A., Wieseler-Frank J., Milligan E.D., Maier S.F. Norman Cousins Lecture. Glia as the "bad guys": implications for improving clinical pain control and the clinical utility of opioids. Brain Behav. Immun. 2007, 21:131-146.
87. Watson C.P., Moulin D., Watt-Watson J., Gordon A., Eisenhoffer J. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain 2003, 105:71-78.
88. Williams J., Haller V.L., Stevens D.L., Welch S.P. Decreased basal endogenous opioid levels in diabetic rodents: effects on morphine and delta-9-tetrahydrocannabinoid-induced antinociception. Eur. J. Pharmacol. 2008, 584:78-86.
89. Wodarski R., Clark A.K., Grist J., Marchand F., Malcangio M. Gabapentin reverses microglial activation in the spinal cord of streptozotocin-induced diabetic rats. Eur. J. Pain 2009, 13:807-811.
90. Woolf C.J., Mannion R.J. Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet 1999, 353:1959-1964.
91. Yao L., Dong W., Lu F., Liu S. An improved acute gouty arthritis rat model and therapeutic effect of rhizoma Dioscoreae nipponicae on acute gouty arthritis based on the protein-chip methods. Am. J. Chin. Med. 2012, 40:121-134.
92. Yrjanheikki J., Keinanen R., Pellikka M., Hokfelt T., Koistinaho J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:15769-15774.
93. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983, 16:109-110.